There was no increased risk of infections with IV iron .
Gastrointestinal AEs were reduced with IV iron .
CONCLUSION Intravenous iron therapy is not associated with an increased risk of SAEs or infections .
Infusion reactions are more pronounced with IV iron
OBJECTIVE To amass all available evidence regarding the safety of intravenous ( IV ) iron preparations to provide a true balance of efficacy and safety .
Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin.
OBJECTIVES To compare oral versus intravenous iron in pre-dialysis patients of chronic renal failure ( CRF ) receiving recombinant human erythropoietin ( rHuEPO ) . METHODS The study was undertaken in 40 adult patients of chronic renal failure . The patients were r and omly divided into two groups A and B of 20 patients each . Group A patients were given oral iron and group B patients were given intravenous iron . All patients in both groups were given recombinant human erythropoietin 2000 IU twice weekly subcutaneously . The study was carried for up to three months . Patients were monitored every month for renal parameters and haematological parameters which included haemoglobin , reticulocyte count and packed cell volume . Ferrokinetic studies were done at baseline and at three months . RESULTS It was observed that haematological parameters showed significant statistical improvement in the intravenous iron group as compared to group A ( oral iron group ) . The ferrokinetic studies revealed that serum iron , serum ferritin and transferrin saturation , decreased significantly in oral iron group , whereas significant increase was seen in group B ( intravenous iron group ) . None of the patients developed any adverse effects because of erythropoietin or iron therapy . CONCLUSIONS Concomitant use of intravenous iron is better than oral iron in CRF patients treated with rHuEPO . The intravenous route of iron administration may be a preferred route along with rHuEPO therapy , more so in the Indian context where prevalence of iron deficiency anaemia is fairly high
There was no increased risk of infections with IV iron .
Gastrointestinal AEs were reduced with IV iron .
CONCLUSION Intravenous iron therapy is not associated with an increased risk of SAEs or infections .
Infusion reactions are more pronounced with IV iron
OBJECTIVE To amass all available evidence regarding the safety of intravenous ( IV ) iron preparations to provide a true balance of efficacy and safety .